Interaction of factors related to the metabolic syndrome and vitamin D on risk of prostate cancer - PubMed (original) (raw)
Interaction of factors related to the metabolic syndrome and vitamin D on risk of prostate cancer
Pentti Tuohimaa et al. Cancer Epidemiol Biomarkers Prev. 2007 Feb.
Abstract
Background: Factors related to the metabolic syndrome and low levels of vitamin D have been implicated as risk factors for prostate cancer. Insofar, no studies have assessed their joint effects on prostate cancer risk.
Methods: We studied (a) the associations of vitamin D with the metabolic syndrome factors body mass index, systolic and diastolic blood pressure, and high-density lipoprotein cholesterol (HDL-C) and (b) the prostate cancer risk associated with these factors and especially their joint effects with vitamin D on risk of prostate cancer. We did a longitudinal nested case-control study on 132 prostate cancer cases and 456 matched controls from a cohort of 18,939 Finnish middle-aged men from the Helsinki Heart Study. The odds ratios (OR) of prostate cancer were assessed via conditional logistic regression analysis.
Results: Apart from HDL-C, there was no linear association between the metabolic syndrome factors and vitamin D levels. In univariate analysis, men in the highest quartiles of body mass index (>28 kg/m(2)) and systolic blood pressure (>150 mmHg) showed a modest increase in risks of prostate cancer, with ORs of 1.37 (P = 0.16) and 1.53 (P = 0.05) when compared with the three lower quartiles, but low HDL-C entailed no prostate cancer risk. However, with all three factors present, the OR was 3.36 (P = 0.02), and jointly with low vitamin D (<or=40 nmol/L), the OR was 8.03 (P = 0.005) compared with those with no metabolic syndrome factors and intermediate levels of vitamin D. There was an interaction between vitamin D and the metabolic syndrome factors so that a clustering of these factors entailed high risk of prostate cancer but only if vitamin D level was low (<or=40 nmol/L). If it was at intermediate levels, the metabolic syndrome factors entailed no prostate cancer risk.
Conclusions: We conclude that the prostate cancer risk associated with factors related to the metabolic syndrome is strongly conditioned by levels of vitamin D.
Similar articles
- Metabolic syndrome and the risk of prostate cancer in Finnish men: a population-based study.
Laukkanen JA, Laaksonen DE, Niskanen L, Pukkala E, Hakkarainen A, Salonen JT. Laukkanen JA, et al. Cancer Epidemiol Biomarkers Prev. 2004 Oct;13(10):1646-50. Cancer Epidemiol Biomarkers Prev. 2004. PMID: 15466982 - Metabolic syndrome predicts prostate cancer in a cohort of middle-aged Norwegian men followed for 27 years.
Lund Håheim L, Wisløff TF, Holme I, Nafstad P. Lund Håheim L, et al. Am J Epidemiol. 2006 Oct 15;164(8):769-74. doi: 10.1093/aje/kwj284. Epub 2006 Sep 4. Am J Epidemiol. 2006. PMID: 16952929 - Circulating vitamin D metabolites in relation to subsequent development of prostate cancer.
Gann PH, Ma J, Hennekens CH, Hollis BW, Haddad JG, Stampfer MJ. Gann PH, et al. Cancer Epidemiol Biomarkers Prev. 1996 Feb;5(2):121-6. Cancer Epidemiol Biomarkers Prev. 1996. PMID: 8850273 - Vitamin D and the epidemiology of prostate cancer.
Schwartz GG. Schwartz GG. Semin Dial. 2005 Jul-Aug;18(4):276-89. doi: 10.1111/j.1525-139X.2005.18403.x. Semin Dial. 2005. PMID: 16076349 Review. - Are men with low selenium levels at increased risk of prostate cancer?
Brinkman M, Reulen RC, Kellen E, Buntinx F, Zeegers MP. Brinkman M, et al. Eur J Cancer. 2006 Oct;42(15):2463-71. doi: 10.1016/j.ejca.2006.02.027. Epub 2006 Sep 1. Eur J Cancer. 2006. PMID: 16945521 Review.
Cited by
- How competing risks affect the epidemiological relationship between vitamin D and prostate cancer incidence? A population-based study.
Voutilainen A, Virtanen JK, Hantunen S, Nurmi T, Kokko P, Tuomainen TP. Voutilainen A, et al. Andrologia. 2022 Jul;54(6):e14410. doi: 10.1111/and.14410. Epub 2022 Feb 28. Andrologia. 2022. PMID: 35229338 Free PMC article. - Systolic and diastolic blood pressure, prostate cancer risk, treatment, and survival. The PROCA-life study.
Stikbakke E, Schirmer H, Knutsen T, Støyten M, Wilsgaard T, Giovannucci EL, McTiernan A, Eggen AE, Haugnes HS, Richardsen E, Thune I. Stikbakke E, et al. Cancer Med. 2022 Feb;11(4):1005-1015. doi: 10.1002/cam4.4523. Epub 2021 Dec 22. Cancer Med. 2022. PMID: 34939344 Free PMC article. - Midlife metabolic factors and prostate cancer risk in later life.
Dickerman BA, Torfadottir JE, Valdimarsdottir UA, Wilson KM, Steingrimsdottir L, Aspelund T, Batista JL, Fall K, Giovannucci E, Sigurdardottir LG, Tryggvadottir L, Gudnason V, Markt SC, Mucci LA. Dickerman BA, et al. Int J Cancer. 2018 Mar 15;142(6):1166-1173. doi: 10.1002/ijc.31142. Epub 2017 Nov 16. Int J Cancer. 2018. PMID: 29114858 Free PMC article. - BMI and serum lipid parameters predict increasing risk and aggressive prostate cancer in Chinese people.
Zhao R, Cheng G, Wang B, Qin C, Liu Y, Pan Y, Wang J, Hua L, Zhu W, Wang Z. Zhao R, et al. Oncotarget. 2017 Aug 2;8(39):66051-66060. doi: 10.18632/oncotarget.19790. eCollection 2017 Sep 12. Oncotarget. 2017. PMID: 29029491 Free PMC article. - Metformin and longevity (METAL): a window of opportunity study investigating the biological effects of metformin in localised prostate cancer.
Crawley D, Chandra A, Loda M, Gillett C, Cathcart P, Challacombe B, Cook G, Cahill D, Santa Olalla A, Cahill F, George G, Rudman S, Van Hemelrijck M. Crawley D, et al. BMC Cancer. 2017 Jul 21;17(1):494. doi: 10.1186/s12885-017-3458-3. BMC Cancer. 2017. PMID: 28732480 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical